header logo image


Page 749«..1020..748749750751..760770..»

134 drivers a week have licence revoked by poor eyesight – Actuarial Post

January 15th, 2020 1:43 am

It is not just experienced drivers that have issues with their eyesight either; on average 12 people a week fail their driving test before it even starts because they cant read a clean number plate from a distance of 20 metres. The DVLA requires drivers to be able to read (with glasses or contact lenses if necessary) a car number plate from 20 metres, have accurate vision to at least decimal 0.5 (6/12) measured on the Snellen scale and an adequate field of vision.

With an estimated 8.9 million (21 per cent) of drivers admitting to not having their eyes tested in the last two years and 1.1 million (3 per cent) never having had their eyes tested at all, it is likely thousands of drivers are unaware they are not safe to be in charge of a vehicle because of poor vision. Drivers can be fined up to 1,000 if they dont inform the DVLA about a medical condition that affects their driving and could be prosecuted if involved in a collision as a result. Eye care professionals believe there should be stricter rules regarding eye check-ups, with 81 per cent of optometrists supporting a change in law so annual eye tests are made mandatory for drivers.

Almost one in four (24 per cent) drivers would put their own life and that of others at risk by waiting until their licence was revoked rather than giving up driving voluntarily because their eyesight had deteriorated so badly they couldnt drive safely. People are also unwilling to report friends and family to the DVLA, allowing them to keep driving even if they thought they couldnt see to drive safely. Only four per cent of people have reported a friend or family member to the DVLA over concerns that their eyesight was too bad to drive.

Steve Barrett, head of motor insurance at Direct Line, commented:If people do not have regular eye tests, they may not even realise their vision is impaired when they get behind the wheel, which leaves them a danger to themselves and other road users.

A simple eye test, that takes a moment in time, can ensure drivers have the appropriate corrective glasses or contact lenses so that their vision is adequate to drive.

Dr Nigel Best, clinical spokesperson for Specsavers said: Our vision can deteriorate slowly, meaning it is sometimes difficult to detect a change ourselves but subtle variations can increasingly affect both perception and reaction time when driving. We welcome this research and hope it will make more road users aware of the risks they run by not having regular eye tests, whether it is potentially losing your driving license or worse, causing a collision on the road.

It takes around 25 minutes for an optician to conduct a thorough vision and eye health check. To take this simple step every two years or more, if recommended by your optician, isnt an arduous task, particularly when you weigh up the potentially negative consequences of driving with impaired vision.

Regional findings

Residents of Brighton are the least likely across the UK to regularly visit the optician, with a third (33 per cent) of people failing to have an eye test in the last two years. Residents of Birmingham (30 per cent), Glasgow (30 per cent) and Leeds (30 per cent) are also risking driving without the right corrective lenses because they have failed to have their eyes tested in the last two years.

Table one: Regional insight into how recently residents have had an eye test

Link:
134 drivers a week have licence revoked by poor eyesight - Actuarial Post

Read More...

Possible treatment for leading cause of vision loss seeks study volunteers – The Tri-City News

January 15th, 2020 1:43 am

A potential new treatment for a disease that robs people of their sight is being tested in Coquitlam.

Age-related macular degeneration (AMD) is, according to the Canadian National Institute for the Blind, the leading cause of vision loss in Canada. More than 1.4 million Canadians suffer from AMD and the diseases prevalence among older Canadians will only grow as Canadas seniors population doubles over the next 25 years. There is no known cure.

People with the dry version of AMD are being sought for a clinical trial led by Coquitlam ophthalmologist Kevin Parkinson. The study involves treatment with an investigational medical device that could possibly help patients retain and, in some cases, improve their visual acuity.

The trial will be conducted on behalf of EMC Inc., a Calgary-based company. Participants will be treated with a computerized electrotherapeutic device the companys engineers have researched, designed and built to treat the symptoms of dry AMD.

The Canadian governments regulator for medical devices, Health Canada, authorized the trial in July. A regulatory panel, the Western Institutional Review Board, which is based in Washington state, will confirm the trials investigators are appropriately qualified and the protocol approved by Health Canada is being implemented correctly. The Coquitlam trial will involve 60 volunteer patients.

Dr. Parkinson is the primary investigator leading the trial. About 30 optometrists in the Metro Vancouver area have been recruited to refer patients with AMD for participation.

The treatment is not intrusive. It requires no drugs as part of its regime. Instead, it employs EMCs own patented micro-current therapy. The idea is as old as electricity but is comparable to a modern-day TENS device. Its both cutting-edge in design and technology, lightweight for ease of use and patient comfort, and simple to operate in the hands of trained personnel.

The goal of the Coquitlam research study is to enroll a sufficient number of subjects to see how safe and effective the investigational device is with people who have dry AMD, said Brent Saik, EMCs optometry consultant. We want to evaluate the devices ability to improve participants eyesight. Each treatment session lasts approximately 30 minutes.

AMD causes damage to the macula, the central part of the retina responsible for seeing details. It limits the sufferers ability to drive a vehicle, recognize faces, read, sew or do fine work. Virtually all AMD begins in the dry form; the Canadian Ophthalmological Society says nine of 10 Canadians who have AMD suffer from the dry version.

Another of the trials objectives is to confirm EMCs mechanism of action theory: that is, treatment with the EMC device improves permeability of the blood vessel membranes and cells, and allows better oxygen and nutrition delivery to the cells. In other words, pulsed micro-current electrotherapy can re-awaken hibernating cells that impair vision.

The likelihood of an individual developing AMD is largely determined by genetic predisposition, ethnicity and health. Caucasians, and those whose parents, grandparents or siblings have had AMD, are at a substantially increased risk of developing the disease. Many studies have asserted that those with a history of smoking are also particularly susceptible.

Participation in the trial is limited so EMC is asking that inquiries be limited to those whose vision is between 20/50 and 20/200. Participants can live anywhere, but must be willing to travel regularly to Coquitlam. There is no cost to the participant, who will be provided with a detailed consent form. Those wanting more information are asked to call 604-685-3937 or email clinicaltrialsemc@gmail.com.

Read this article:
Possible treatment for leading cause of vision loss seeks study volunteers - The Tri-City News

Read More...

Kitty’s eye condition discovered during a routine trip to the optician – themediatimes

January 15th, 2020 1:43 am

advertisement

A little girls Marfan syndrome was identified after she had her eyes tested for the first time in Ilkeston.

Kathleen OHara, known as Kitty, was only three years old when she first visited Specsavers with her mother, Amy, for a routine eye exam in November 2017.

advertisement

I noticed that Kitty had vision problems, she held the books very close to her face and looked up, so I took her to the optician, said Amy.

Very young children who can identify simple forms can have an eye exam at opticians. An eye test examines the overall health of the eye as well as vision. When examining Kittys eyes, Specsavers optometrist, Navin Nehra, found a problem with his crystal lenses, structures in the middle of the eye that focus light on the retina, these are the same structures that can be affected. by cataracts, usually when we get older. But with Kittty, it was not a cataract, the lenses themselves were not in the right position and a referral to the Queens Medical Center (QMC) in Nottingham was made, where Kitty was seen in the week.

About one in 5,000 children experience this type of lens shift, known as ectopia lentis, so its really very rare, says Navin. This is the first time I have seen the problem with a client in my ten year career.

At the hospital, the doctor talked about a few ways to explain Kittys symptoms, before diagnosing connective tissue disorder, Marfan syndrome. Although there is no cure, without treatment, victims risk sudden death and may go unnoticed because of its obscurity.

Since the diagnosis, Kitty has had countless doctors and hospital appointments to improve her chances of a healthy life as she ages. She has had two eye surgeries, uses a wheelchair because she gets tired easily and takes medicine for her heart.

Amy adds, If it wasnt for me to have her take the eye test, we might not have been wiser. The earlier it is detected, the better, so I am very grateful for the quick reference made by Navin.

Very few people know about Marfan syndrome, so we really want to raise awareness of the signs it could save lives.

As a rule, people with the disease are tall with long fingers. The eyes are often the first indication, as lenses tend to slip, although not everyone with Marfan syndrome has eye problems.

The syndrome is a genetic disorder and about three-quarters of people inherit the gene from their parents, while one-quarter have no family history of the disease. Its signs are not always present in early childhood. Some people do not develop functionality, including heart problems like an aortic enlargement, until they are adults.

Without early diagnosis and treatment, people may be at risk for life-threatening complications. The earlier certain treatments are started, the better the results.

Krishna Parmar, manager of Specsavers Ilkeston, said: Kitty is a wonderfully resilient little girl and we are delighted that she is getting the treatment she needs. She always brightens our day when she comes to the store.

If you notice any changes in your childs eyes or eyesight, it is important to check them as soon as possible.

.

advertisement

Link:
Kitty's eye condition discovered during a routine trip to the optician - themediatimes

Read More...

Lizzie Cundy reveals fillers in eye sockets BLINDED her as she battled to stay young after catching lover – The Sun

January 15th, 2020 1:43 am

WITH her eyes swollen beyond recognition and her sight failing by the minute, reality star and TV presenter Lizzie Cundy was petrified.

Just two days earlier, the 51-year-old mum of two had had filler injected in her eye sockets in an attempt to get rid of her under eye bags.

11

Lizzie's self-esteem was in tatters after her boyfriend, nightclub owner Jeremy Gordeno, had also been seeing the 21-year old daughter of a previous lover in October last year.

"I was devastated," she says quietly.

"He could have been her granddad. It was such a betrayal. I couldnt sleep, my self-confidence was at rock bottom."

A friend recommended a new cosmetic treatment to boost her self-esteem Lizzie quickly booked an appointment.

"She told me she had had some filler in her under eye area to take away the bags and that it took 10 years off you. Shed actually had it done and she looked great," says Lizzie.

"It was a case of wanting a quick fix."

11

11

The practitioner had rooms on Londons swanky Harley Street, yet within minutes of the treatment Lizzie knew something was wrong.

Her under eye area had puffed up beyond recognition and as the hours went by her vision was blurring, leaving her panicked and terrified.

"I literally didn't know whether or not I would go permanently blind," she says, her eyes filling with tears at the memory.

"It was like something from a horror film my vision had gone blurry, I was blinking and blinking trying to focus and I just couldnt. I was panic-stricken."

Now she was desperately relying on the intervention of an experienced cosmetic doctor to save her sight.

"I thought of everything I would lose being able to look at my gorgeous boys all because I had been trying to improve the way I look. My heart was beating so fast. It was horrendous."

11

While little known, botched filler procedures have led to 200 documented cases of vision loss in recent years, with 35 in the UK alone being left blind in one eye or both.

It happens when filler is mistakenly injected into an artery, blocking crucial blood circulation to the optic nerve.

This can happen even when the injected area is much lower in the face.

"I didnt know any of this," Lizzie says. "Now it makes me sick to think I risked my sight."

Her terrifying near-miss which unfolded just three months ago - is one reason Lizzie has lent her voice to Fabulous's Had Our Fill campaign, calling for tighter regulations of the cosmetic treatment industry and urging people to do their research before they submit to potentially life-changing procedures.

"I want what happened to me to be a warning to others," she says.

"It was the scariest time and I wouldn't want anyone else to go through what I did."

11

No stranger to cosmetic interventions, Lizzie - who openly admits she had a boob job following the birth of sons Josh, 24, and 19-year-old James - is candid about the fact that she first turned to facial treatments in the wake of the 2010 breakdown of her marriage to former footballer Jason Cundy.

"I literally didn't sleep, I felt really tired, and I looked awful, so I had a bit of Botox in my forehead and suddenly I looked better. People told me I looked good considering everything I was going through," she recalls.

It quickly became 'shall I have a little bit more?'

She quickly moved on to facial filler in her cheeks and laughter lines - and it didnt take long before she was addicted to both fillers and Botox.

"It quickly became 'shall I have a little bit more?'. I would leave it a month and then I'd start feeling anxious and want a little top-up," she reveals.

But little did she know that this chasing youth would almost cost her her sight.

11

Had Our Fill campaign

BRITAIN'S Botox and filler addiction is fuelling a 2.75billion industry.

The wrinkle-busting and skin plumping treatments account for 9 out of 10 cosmetic procedures.

50% of women and 40% of men aged 18 to 34 want to plump up their pouts and tweak their faces.

Fillers are totally unregulated and incredibly you dont need to have ANY qualifications to buy and inject them.

83% of fillers are performed by people with no medical training, often in unsanitary environments - with devastating results.

Women have been left with rotting tissue, needing lip amputations, lumps and even blinded by botched jobs.

Despite the dangers, there is no legal age limit for dermal filler, which is why Fabulous has launched Had Our Fill, a campaign to:

We're working in conjunction with Save Face and are backed by the Royal Society for Public Health (RSPH), British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS) and British Association of Aesthetic Plastic Surgeons (BAAPS).

We want anyone considering a non-surgical cosmetic treatment to be well-informed to make a safe decision.

Weve Had Our Fill of rogue traders and sham clinics - have you?

Lizzies television work, reporting from the red carpet, also left her under pressure to look younger.

"I was told by one boss that I had to take a few years off my age because it's a young industry. I felt that younger people were snapping at my heels," she says.

"The irony was that I'd never worked so much - yet inside I was really unhappy and lonely.

"Looking back, I probably should have spoken to a therapist but instead I thought another appointment with the cosmetic doctor would sort me out."

Then, in 2012 her straight-talking mum told her she had gone too far.

"I did a big photo shoot and afterwards my mum said, 'Lizzie you look different and it's not in a good way'.

"It was the wake-up call I needed, and I decided to embrace a more natural look, she reveals.

"A lot of people said I looked better so that boosted my confidence. I was in a much better place."

11

11

But when she discovered Jeremy, who she met in a bar near her Hampshire home in December 2018, had been cosying up to another woman, her old securities came flooding back and she returned for filler.

Yet from the moment the 15-minute treatment was administered by the therapist - who The Sun has chosen not to name - Lizzie says she felt uncomfortable.

"I could feel the injections were very near my eye - the needle was brushing on my lashes. I kept saying, 'Is this right?' but she just reassured me," she recalls.

Leaving the clinic, Lizzie could already feel her eyes swelling.

"I rang on my way home and said it didnt feel right - but the woman said that was normal. Then as soon as I got home, I looked in the mirror and it looked like there was a shelf under my eyes. It was also slightly burning."

Panicked, Lizzie rang the clinic again, only to be told to give her treatment time to settle.

"By the next day they looked even more swollen, so I actually went to my GP. He thought I might have a sinus problem and gave me antibiotics."

Back home her eyes continued to swell.

"I'd never had such a reaction like this. I literally had to put Vaseline over my face and all these different things to try and help. It just kept getting worse."

When she woke up the following morning her vision was blurry.

11

Fillers by numbers

2.75 billion - estimated value of UKs non-surgical cosmetic industry

59% - 13 to 24 year olds see lip fillers as routine as getting a haircut or manicure

68% - young people say friends have had fillers

160 - different types of dermal filler available for use in Europe, compared to only 10 in the US where they have tighter regulations

1,617 - complaints received by Save Face last year regarding unregistered practitioners

1.2 million - posts for #lipfillers on Instagram

3.9 million - Google searches for lip fillers in UK last year

40% - 13 to 19 year olds say images on social media cause them to worry about body image

She says: "I had to get up early for filming and my eyesight was already a bit blurry and my eyes were more swollen than ever.

"I was filming a documentary about Meghan Markle and kept thinking 'I cant let people down'. The make-up lady had done her best to cover the swelling but when I was looking at the auto cue, I literally couldn't read it.

"I was really blinking, trying to focus and it was really difficult and I was thinking 'I can't properly see'. "It was like something from a horror movie and I realised I had to act fast."

11

Lizzie rang the number of a cosmetic doctor who had helped a friend when she had lip filler that had gone wrong.

"I got his number, sent him a picture and he said, 'You have to come in now'," she recalls.

She got there as quickly as she could, only to be told by the doctor that the treatment was so dangerous that he had to try to dissolve it instantly.

Worse, there was no guarantee that the treatment would work.

"He said he could only do his best, but he had to attempt to get rid of the filler now before it did any more damage," says Lizzie.

"I was petrified. I had to keep my eyes open while he administered more injections round my eye socket praying it wouldnt make things worse."

Thankfully the treatment combined with a collagen wave, which uses radio frequency energy to smooth skin did the trick.

"Literally it was like watching magic at work, you could see it all going. The doctor told me I was incredibly lucky.I vowed never again."

11

Three months later she is still counting her blessings as well as vowing she is done with cosmetic injectables.

"Whats happened has given me a bit of kick up the backside - I know I have to have a bit more self-esteem because cosmetic surgery isn't the answer. Never say never but for now I want to learn to love who I am and to be the best I am at my age."

Lizzie is using vitybox as an alternative source of collagen.

Here is the original post:
Lizzie Cundy reveals fillers in eye sockets BLINDED her as she battled to stay young after catching lover - The Sun

Read More...

Type 2 diabetes symptoms: The sign in your eyes that could signal the condition – Express

January 15th, 2020 1:43 am

One symptom of type 2 diabetes you need to watch out for is blurred vision. This refers to the loss of sharpness and inability to see fine details. Diabetes UK report that one in three people will have complications with their eyes by the time theyre diagnosed with type 2 diabetes.

Blurred vision can happen in either one eye (unilateral) or both (bilateral) eyes, and is caused by high levels of blood sugar with those with type 2 diabetes (diagnosed or not) resulting in the lens inside the eye to swell.

Diabetes UK point out there are other common symptoms of diabetes people should be aware of:

If you notice blurred vision, it could indicate that you have diabetes that isnt controlled.

Persistent high blood sugar levels can damage the back of the eye (retina), medically known as diabetic retinopathy.

The retina needs a constant supply of blood to function, which it receives through a network of tiny blood vessels.

Over time, uncontrolled type 2 diabetes (signified by persistent high blood sugar levels) can damage the blood vessels servicing the retina.

READ MORE:How to lose visceral fat: Best oil to cook with if you want to reduce harmful belly fat

This happens in three main stages:

Background retinopathyBackground retinopathy is when tiny bulges develop in the blood vessels, which may bleed slightly but don't usually affect vision.

Pre-proliferative retinopathyPre-proliferative retinopathy is when more severe and widespread changes affect the blood vessels, including more significant bleeding into the eye.

Proliferative retinopathyProliferative retinopathy is when scar tissue and new blood vessels, which are weak and bleed easily, develop on the retina. This can result in some loss of vision

The NHS point out that it usually takes several years for diabetic retinopathy to reach a stage where it could threaten your sight, but it can cause blindness if left undiagnosed and untreated.

Anyone with type 2 diabetes is potentially at risk of developing diabetic retinopathy.

However, those with the highest chance of developing this complication of diabetes include those who:

Read the rest here:
Type 2 diabetes symptoms: The sign in your eyes that could signal the condition - Express

Read More...

Access And Actionability Are Key For Genetic Testing And Precision Medicine – Forbes

January 15th, 2020 1:42 am

Over the past two decades, the field of medical genomics underwent nothing less than a revolution in terms of both technological advancement and accumulated knowledge. This revolution holds the promise of changing the entire medical practice, and while the industrycontinues to improve genome sequencing technologies and decrease the price of sequencing a genome, other challenges are lurking that hinder the prospects of this revolution and undermine the efforts of wide-scale integration of genomics into mainstream medicine.

To emphasize this point further, even though the technologies to help diagnose patients with rare genetic diseases exist, the rate of underdiagnoses and misdiagnoses is still alarmingly high, and patients who receive diagnoses end up waiting too long for them, sometimes years. These extensive diagnostic journeys directly impact the ability to recruit patients for clinical trials, and thus the ability to develop more treatments for rare diseases. To date, only 5% of more than 7,000 known rare genetic diseases have FDA-approved treatments.

At my company, a leading digital health company, our mission is to end the diagnostic odyssey for undiagnosed pediatric patients with rare diseases. I've seen that the main contributors to this state of affairs are the excruciatingly long wait times for genetics appointments, coupled with the significant workforce shortage of experts in the field.

To reach more than 400 million patients globally (50% of whom are estimated to be young kids) with earlier intervention to improve outcomes and help many of them live relatively healthy and productive lives, the diagnosis must shift from the geneticists clinic to the primary point of care, or at least it must be initiated much earlier by primary care physicians.

Without adopting technological solutions that will support the integration of genomics into mainstream medicine, genomics will never live up to its promise and become a standard of care. In my opinion, realizing that vision will be a balancing act between the affordability for payers, accessibility for providers and actionability for patients, and it will depend on technological solutions combining AI-based phenotyping, as well as connecting front-line providers with human experts in genetics, alongside the most advanced genome sequencing technologies.

High Throughput Genetic Testing

As noted, genome sequencing technologies have made huge strides over the last two decades. The affordability of genomics is now increasingly dependent on the ability to sift through and interpret vast amounts of data produced from a genome, and to determine which data is pertinent for a medical diagnosis and for disease treatment a task fitting for AI.

Indeed, in the last few years, we have witnessed many AI-driven solutions sprouting to address this problem. Some of these solutions are home-grown, in leading laboratories such as Invitae, GeneDx and PerkinElmer Genomics. (Full disclosure: PerkinElmer Genomics uses FDNA's technology in its genetic analysis.) Others are developed as software platforms by vendors such as Sophia Genetics, Fabric Genomics, Congenica and Emedgene.

Harnessing AI to perform data analysis challenges has proven to be very successful and is a direct contributor to the affordability of genetic testing today, as well as the gradually increasing rate of reimbursement by payers. I believe AI will continue to play a key role in driving down prices to the $100 range, which will make genomics extremely affordable, both for health systems and for individuals paying out-of-pocket.

Phenotyping Driven By AI

AIs impact goes far beyond applying machine learning algorithms that sift through genetic variations and proprietary knowledge bases of pathogenicity. As more OMICS technologies stack up with genomics, and more AI modalities like natural language processing and computer vision image analysis are integrated directly into the genome analysis pipeline, we will see an increasing standardization of data across disparate data silos and a closing of the genotype-phenotype gap between the clinic and the lab. This trend will drive genomic data to become more actionable for patients and allow them to make informed decisions about their health.

Much of todays phenotyping is performed by humans and is inherently subject to biases such as age, gender and ethnicity. If we approach this problem with legal and ethical rigor, care and are cautious of patient privacy, and with respect to the providers and their workflow, AI could enhance human skills and capabilities. I think that helping primary care providers collect, structure and analyze phenotypic information of patients with rare diseases is an area worth prioritizing.

Connecting The Expert Community

Finally, technology is more than AI. Technology is also an enabler for fostering connections and interactions between humans. Some tasks in practicing medicine must be left to humans, but even then, technology can assist. An alternative abbreviation of AI (augmented intelligence) is my preferred one. It implies a symbiotic relationship between people and machines, making each other stronger, rather than threatening to replace each other.

Tailoring a solution combining all three components (genomics, AI-based phenotyping and community connection) like the one described above is not an easy task, and it depends on the ability of stakeholders from many disciplines to work together, share data and collaborate on research and development.

To achieve this, a best-of-breed approach should be taken, and not only should data be shared, but a global collaboration between commercial companies, academic research institutions and caregivers should occur. The integrity of the data, ethical and privacy policies, and trust in workflow should be established. This requires an open dialogue between all parties involved, as well as a fast-pace framework to allow developers to move quickly in building these tools.

Certainly, working with different stakeholders with sometimes conflicting interests is challenging, but the one common goal we all have is helping patients, especially kids with rare and undiagnosed genetic diseases.

Read more from the original source:
Access And Actionability Are Key For Genetic Testing And Precision Medicine - Forbes

Read More...

Cleveland Clinic Study Identifies Genetic Anomaly Associated with Poor Response to Common Asthma Treatment – Health Essentials from Cleveland Clinic

January 15th, 2020 1:42 am

Nima Sharifi, M.D.

A new Cleveland Clinic study has uncovered a genetic anomaly associated with poor response to a common asthma treatment. The findings, published in Proceedings of the National Academy of Sciences, showed that asthmatic patients with the gene variant are less likely to respond to glucocorticoids and often develop severe asthma.

The research team, led by Nima Sharifi, M.D., of Cleveland Clinics Lerner Research Institute, identified that the gene variant HSD3B1(1245A) is associated with glucocorticoid response and may be clinically useful to identify patients most likely to benefit from other treatments.

Glucocorticoids, which modulate systemic inflammatory response, are commonly prescribed to treat severe asthma. However, until now we have not understood why many patients do not benefit from them, said Dr. Sharifi, senior author of the article. These findings make the case for genetic testing and personalized treatment and provide important information for identifying which patients should be treated using different therapies.

In the study, Dr. Sharifi and his collaborators retrospectively analyzed the association between patient genomes and lung function in more than 500 asthmatic patients who received daily oral glucocorticoids treatment or no glucocorticoids treatment.

Joe Zein, M.D.

They found that a change to the gene HSD3B1 specifically the HSD3B1(1245A) variant is associated with poor lung function and glucocorticoid treatment resistance. The analysis revealed that among patients receiving glucocorticoids, those with the variant had poorer lung function than those who did not have the genetic anomaly, suggesting that it contributes to resistance and helps drive the progression to severe asthma.

Previous studies have shown that HSD3B1 encodes an enzyme that converts less active hormones called androgens into more powerful androgens. While additional research is necessary, the team suspects that HSD3B1(1245A)s effect on lung function may be attributed to inhibition of this process.

This study is the first to provide genetic evidence suggesting that variants related to androgen synthesis affect glucocorticoids treatment resistance in asthma or any other inflammation-related disease, said Joe Zein, M.D., first author on the study and a practicing pulmonologist in Cleveland Clinics Respiratory Institute. These findings provide us with important new information that may lead to more tailored treatments for asthma patients and the ability to prevent the development of severe disease.

Asthma is a chronic condition that causes the airways of the lungs to narrow, the lining of the airways to become inflamed and the cells that line the airways to produce more mucus, making it difficult to take in enough air. According to the CDC, about 25 million people in the U.S. have asthma, including more than six million children. Asthma accounts for nearly two million emergency department visits each year.

Previously, Dr. Sharifis laboratory has extensively studied the role of HSD3B1 in prostate cancer. In 2013, he made the seminal discovery that prostate cancer cells with the HSD3B1(1245C) variant survive androgen deprivation therapy, the first line of defense against prostate cancer, by producing their own disease-fueling androgens. He has spent more than seven years studying and publishing peer-reviewed articles on the variants effect in prostate cancer.

Dr. Sharifi holds the Kendrick Family Chair for Prostate Cancer Research at Cleveland Clinic and directs the Cleveland Clinic Genitourinary Malignancies Research Center. He has joint appointments in the Glickman Urological & Kidney Institute and Taussig Cancer Institute. In 2017, he received the national Top Ten Clinical Achievement Award from the Clinical Research Forum for his discoveries linking HSD3B1(1245C) with poor prostate cancer outcomes.

Dr. Zein is a member of the Cleveland Clinic Asthma Center, which provides a comprehensive approach to asthma management and care along with innovative research, offering patients access to the most advanced diagnostic testing and innovative treatments.

This study was supported by the National Heart, Lung, and Blood Institute and the National Cancer Institute, both of the National Institutes of Health.

Link:
Cleveland Clinic Study Identifies Genetic Anomaly Associated with Poor Response to Common Asthma Treatment - Health Essentials from Cleveland Clinic

Read More...

Scientists discover six genetic links to anxiety – The Hill

January 15th, 2020 1:42 am

Researchers say theyve discovered six genetic variants associated with the development of anxiety disorders in what they call the largest study of anxiety traits.

In a study published Tuesday in the American Journal of Psychiatry, researchers examined genetic and health data from 200,000 U.S. veterans. The data was compiled by the Million Veteran Program, a research groupfunded by the federal government to determine how genes, lifestyle and military exposures affect health and illness.

While there have been many studies on the genetic basis of depression, far fewer have looked for variants linked to anxiety, disorders of which afflict as many as 1 in 10 Americans, Murray Stein, a staff psychiatrist in the VA San Diego Healthcare System, said in a statement.

In the analysis, researchers discovered six genetic variants associated with higher risks of developing anxiety disorders. The variants related to anxiety disorders were found on chromosomes 1, 3, 6, 7 and 20. The studys authors called it an important step forward in understanding how genes contribute to mental conditions.

The variant on chromosome 7 is identified to be correlated with higher occurrences of bipolar disorder and schizophrenia.

Its also associated with the reception of estrogen, but researchers were reluctant to draw the conclusion on whether that could explain why women are twice as likely than men to be affected by anxiety disorders. While female veterans were included in the study, more than 90 percent of the participants were men. The studys authors said more research is needed on the topic.

The study also found that five of the genetic variants were found in white Americans, while an additional variant was found in African Americans.

Minorities are underrepresented in genetic studies, and the diversity of the Million Veteran Program was essential for this part of the project, Dan Levey, of the VA Connecticut Healthcare Center and Yale University, said in a statement.The genetic variant we identified occurs only in individuals of African ancestry, and would have been completely missed in less diverse cohorts.

According to the Anxiety and Depression Association of America, almost 40 million people in the U.S. experience an anxiety disorder in any given year.

See original here:
Scientists discover six genetic links to anxiety - The Hill

Read More...

Co-Diagnostics" genetic detection technology on display at international agriculture conference – Proactive Investors USA & Canada

January 15th, 2020 1:42 am

A presentation by a Bayer Crop Science rep described the company's successful Multiplex PCR genetic detection

Incs () BHQplex CoPrimer technology, which is used in diagnostics tests utilizing DNA or RNA, was the star of a presentation from Bayer Crop Science at an agricultural presentation on Tuesday.

The presentation, titled "CoPrimer Assays for Multiplex PCR," was put on by a Bayer representative at the International Plant & Animal Genome XXVIII conference this weekin San Diego.

It described a study that involved developing genotyping assays which detect genetic sequences using the Utah-based companys CoPrimer technology. That detection process includes includes multiplex PCR (polymerase chain reaction), a system for detecting multiple genetic sequences all at once, rather than having to do a new test for each particular sequence.

"We are excited to announce this third-party validation, the importance of which cannot be overstated, and which further supports our confidence in the uniqueness and superior advantages of our patented CoPrimer platform technology, CEO Dwight Egan said in a statement. Bayers commitment to a world where more sustainable farming practices and more adaptive, resilient plants are part of the solution to making hunger a thing of the past aligns perfectly with our mission to improve the lives and quality of life in communities across the world.

Co-Diagnostics technology is being licensed by LGC Biosearch Technologies, a biotechnology company based in the UK.

"With partners like LGC, including their globe-spanning footprint in over 200 countries, and validation from such an important force in the world of agriculture as Bayer, we believe that Co-Diagnostics is better positioned than ever to leverage our technology platform and establishing the Company as a valuable player in the world of AgBio, Egan said.

Contact Andrew Kessel at [emailprotected]

Follow him on Twitter @andrew_kessel

See original here:
Co-Diagnostics" genetic detection technology on display at international agriculture conference - Proactive Investors USA & Canada

Read More...

Wiping out scrapie in goats, the genetic way – Fence Post

January 15th, 2020 1:42 am

More consumers are developing a taste for goat cheese, milk, and meat as they become aware of the high protein and great taste of these products. While U.S. goat producers are enjoying this steady trend, they remain focused on keeping their animals healthy, especially from scrapie a fatal brain disease that affects goats and sheep.

The goat industry is one of the fastest growing animal industries in agriculture, said Stephen White, an Agricultural Research Service geneticist. Not too many years ago, there were only a few hundred thousand goats in the country. But in January 2018, goats and kids totaled 2.62 million head.

Meat and dairy are the biggest markets, followed by mohair, but goats serve in other unique capacities, said ARS veterinary medical officer David Schneider. Goats are being used to manage weedy areas along highways, get rid of kudzu in the Southeast, and even mow lawns. Theyre also used as pack animals to carry supplies through rugged areas.

For any of these businesses, a single outbreak of scrapie could be devastating.

There is no cure or treatment for scrapie, which is in the same family transmissible spongiform encephalopathies (TSEs) or prion diseases as mad cow disease. TSEs are rare degenerative brain disorders characterized by tiny holes that give the brain a spongy appearance.

Most often scrapie is transmitted through birth fluids to other goats and sheep, and it can remain infectious in the environment for many years. It was first recognized in sheep in Great Britain and other European countries more than 250 years ago and was first diagnosed in U.S. sheep in 1947 in a Michigan flock.

All animals that get scrapie die. But there is good news from ARS. White and Schneider, who both work at ARSs Animal Disease Research Unit in Pullman, Wash., are the first to demonstrate by infectious disease challenge that goats with the S146 allele (a different form of a gene) are less susceptible to scrapie over a usual goat lifetime. They also tested the K222 allele in goats. Their research shows that goats with one copy of either the S146 or K222 allele did not develop scrapie after being challenged with infection at birth. The study was published in The Veterinary Journal in 2018.

Commercial goats raised for either meat or milk age out of herd participation as milkers, dams of commercial offspring, or as sires by around 6 years of age, White said. In this ongoing ARS research, goats with the resistance alleles have lived beyond this commercial lifetime up to 7 years with no clinical disease and without getting sick.

The only countries considered to be scrapie free are Australia and New Zealand. Currently, if one goat is diagnosed with scrapie on a U.S. farm, all goats are quarantined for life or euthanized. You couldnt restock your operation with any susceptible animal, White said. The farmers operation would be over.

This research is good news for both goat and sheep producers because it could help with eradication efforts. Before U.S. producers can take advantage of import and export markets, scrapie must be eradicated from the United States and meet the World Organisation for Animal Health (OIE) criteria for disease freedom.

I think for the sheep industry alone, thats about $10 to $20 million annually in lost revenue, Schneider said.

ERADICATION EFFORTS

The U.S. Department of Agricultures Animal and Plant Health Inspection Service heads the National Scrapie Eradication Program. The agency reports that the prevalence of scrapie has decreased significantly since 2002 through eradication efforts. According to OIE rules, to be declared free of scrapie a country must conduct extensive surveillance for the disease and have had no scrapie cases for seven years, Schneider said.

In sheep, genetic resistance was discovered years ago. A test was then developed to allow U.S. sheep producers to test flocks and breed for the resistance allele. Now if theres a scrapie outbreak on a farm, sheep that have the resistant genotype do not have to be quarantine or euthanized.

The goat industry is hoping that APHIS will recognize the S146 and K222 genetic alleles and give the resistance goats the same get out of jail card that sheep have, White said.

In 2007, White and Schneider started their study by challenging goat kids at birth with a mega dose of scrapie. The ongoing study consists of three genotype groups: goats with the protective S146 allele, goats with the K222 allele, and a control group with the common U.S. goat allele.

Most of the goats with the S146 or K222 allele lived a very long time and did not contract scrapie. Those that died were euthanized due to other natural causes. In contrast, all animals in the control group got scrapie within two years.

The S146 and K222 alleles had previously been associated with scrapie resistance in goats, but resistance to challenge had not been scientifically demonstrated, White said. Were the only ones, to our knowledge, testing these alleles for scrapie resistance to challenge with scrapie from anywhere in the Western Hemisphere. Also, our research is one of the longest running studies, he added.

In 2016, the U.S. Animal Health Association passed a resolution declaring that the evidence for these two alleles is compelling and should be incorporated into the scrapie eradication program, White said. Last year, a European Food Safety Authority panel of scrapie experts determined that there was enough evidence for the two alleles, plus a third known as D146, to be considered resistance alleles for classical scrapie in goats. The panel, which cited ARS research, concluded that these are resistance alleles and recommended they be used in scrapie control and eradication programs.

A DNA test was developed to identify animals with the S146 and K222 alleles and became commercially available in 2018. ARS scientists did not develop the test, but they played a major role in making sure it worked and helping to get it to the goat industry.

This ARS research is a definitive demonstration of goat scrapie resistance, Schneider said. Its important to farmers, their networks, the goat and sheep industries, and other countries with goat scrapie problems.

We have a long-time cooperation with the Canadian Food Inspection Agency, Schneider said. Weve been asked to help them with their in-house testing so they can apply the data to their scrapie eradication program.

Scientists continue to study the goats in the project to find out how long theyll live. This is ARS making an impact serving a role in long-term experiments that only ARS can and its happening now, Schneider said.By Sandra Avant, formerly with ARS Office of Communications.

Go here to see the original:
Wiping out scrapie in goats, the genetic way - Fence Post

Read More...

High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE – Rheumatology Advisor

January 15th, 2020 1:42 am

High genetic risk score (GRS) may predict organ damage, end-stage renal disease, and all-cause mortality in patients with systemic lupus erythematosus (SLE), according to study results published in Annals of Rheumatic Disease.1

Investigators genotyped data of a discovery cohort and a replication cohort that included patients with SLE and healthy controls. Patients with SLE (n=1001) were enrolled in the discovery cohort from various clinics in Sweden; healthy controls (n=2802) were enrolled from blood donor centers in the same areas. The replication cohort included 5524 patients with SLE and 9859 healthy controls of European descent, initially enrolled for a study published in 2017.2 Genotyping data were collected from both cohorts using a 200K Immunochip single nucleotide polymorphism array. Cumulative GRSs were assigned to each study participant based on 57 SNPs with known associations to SLE. Risk allele counts of the 57 SNPs were calculated for each participant by summing the total number of risk alleles. Ordinal and logistic regression were used to assess GRS differences between patients and healthy controls.

Results indicated that SLE was more prevalent in the high GRS quartile compared with the low GRS quartile in both the discovery (odds ratio [OR], 12.32; 95% CI, 9.53-15.71; P =7.910-86) and replication (OR, 7.48; 95% CI, 6.73-8.32; P =2.210-304) cohorts. In the discovery cohort, compared with patients in the low GRS quartile, those in the high GRS quartile had a 6-year earlier mean disease onset (33 vs 39 years; P =4.310-5), higher prevalence of damage accrual (OR, 1.47; 95% CI, 1.06-2.04; P =2.010-2), and higher prevalence of any renal disorder (OR, 2.22; 95% CI, 1.50-3.27; P =5.910-5), end-stage renal disease (OR, 5.58; 95% CI, 1.50-20.79; P =1.010-2), and proliferative nephritis (OR, 2.42; 95% CI, 1.30-4.49; P =5.110-3).

Patients in the high GRS quartile vs the low GRS quartile of the discovery cohort were also more likely to have a positive antiphospholipid antibodies test (OR, 1.84; 95% CI, 1.16-2.9; P =9.410-3), with more than doubled odds of being triple positive (OR, 2.27; 95% CI, 1.02-5.09; P =4.610-2). In survival analyses conducted in the discovery cohort, compared with the low GRS quartile, the high GRS quartile displayed earlier onset of first organ damage (43 vs 51 years), first cardiovascular event (45 vs 51 years), nephritis (31 vs 39 years), and end-stage renal disease (43 vs 64 years). Decreased overall survival was also observed in the high-to-low quartile comparisons (hazard ratio, 1.83; 95% CI, 1.02-3.30; P =4.310-2).

These data support the prognostic capacity of GRS for SLE outcomes. The highest GRS quartile was strongly associated with poorer outcomes, including organ damage, cardiovascular events, renal dysfunction, and all-cause mortality. Our results indicate that genetic profiling may be useful for predicting outcomes in patients with SLE, the investigators wrote.

References

1. Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus [published online December 11, 2019]. Ann Rheum Dis. doi:10.1136/annrheumdis-2019-216227

2. Langefeld CD, Ainsworth HC, Vyse TJ. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021.

Excerpt from:
High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE - Rheumatology Advisor

Read More...

Filling In The Gaps Of Asia’s Genetic Map – Asian Scientist Magazine

January 15th, 2020 1:42 am

AsianScientist (Jan. 14, 2019) An international team of scientists has sequenced the genomes of almost 2,000 Asians to find clues about Asian ancestry, health and disease. Their findings are published in Nature.

Despite forming over 40 per cent of the worlds population, Asian people have previously accounted for only six per cent of the worlds recorded genome sequences.

To raise the representation of Asian genomes in biomedical studies, Nanyang Technological University, Singaporetogether with Macrogen, South Korea; Genentech, US; and MedGenome, India/USlaunched the GenomeAsia 100K consortium in 2016. The consortium aims to understand the genome diversity of Asian ethnicities by sequencing 100,000 genomes of people living in Asia.

GenomeAsia 100K is a significant and far-reaching project that will affect the well-being and health of Asians worldwide, said NTU Professor Stephan C. Schuster, the consortiums scientific chairman and a co-leader of the study.

In the present study, the researchers analyzed the genomes of 1,739 people, which represents the widest coverage of genetic diversity in Asia to date. Genomic DNA was extracted from blood and saliva samples, then sequenced in the laboratories of the four consortium members. The digital sequencing data were subsequently sent to Singapore for processing and storage.

Zooming in on the frequencies of known genetic variants related to adverse drug response, the team reported that Warfarin, a common anticoagulant drug prescribed to treat cardiovascular diseases, has a higher frequency of appearance in individuals with North Asian ancestry, such as Japanese, Korean, Mongolian or Chinese.

Using this data, scientists can now screen populations to identify groups that are more likely to have a negative predisposition to a specific drug. Knowing a persons population group and their predisposition to drugs is extremely important if personalized medicine is to work, Schuster emphasized.

In addition, the researchers discovered that Asia has at least ten ancestral lineages, whereas northern Europe has a single ancestral lineage. Moving forward, the GenomeAsia 100K consortium will continue to collect and analyze up to 100,000 genomes from all of Asias geographic regions to fill in the gaps of the worlds genetic map and to account for Asias unexpected genetic diversity.The article can be found at: GenomeAsia100K Consortium (2019) The GenomeAsia 100K Project Enables Genetic Discoveries Across Asia.

Source: Nanyang Technological University; Photo: Shutterstock.Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

More here:
Filling In The Gaps Of Asia's Genetic Map - Asian Scientist Magazine

Read More...

Suicide rates sharply higher than average in teens, young adults with diabetes – Reuters

January 15th, 2020 1:41 am

Young people with diabetes are at greater risk than peers without the disease of developing mental health problems or attempting suicide as they transition into adulthood, a Canadian study suggests.

Based on data for more than 1 million young people born in Quebec, researchers found that being diagnosed with diabetes is associated with increased odds of being diagnosed in an emergency room or hospital with a mood disorder like depression. Its also linked to higher odds of being admitted to a hospital for a suicide attempt, according to the report in Diabetes Care.

Between the ages of 15 and 25, adolescents and young adults with diabetes are 325% as likely to attempt suicide as their same-age peers, and 133% as likely to suffer from a mood disorder, said Dr. Marie-Eve Robinson, a pediatric endocrinologist at the Childrens Hospital of Eastern Ontario, in Ottawa, Canada, who led the study.

Past research has explored risks for psychiatric disorders in individuals with and without type-1 diabetes, Robinson and her colleagues write in Diabetes Care, but the risks during the transition from adolescence to adulthood have not been assessed.

In addition to challenges inherent to adolescence, young adults with diabetes who transition to adult care need to adapt to a new adult-care provider and a treatment facility, Robinson told Reuters Health.

Young adults tend to perceive pediatricians as more family-centered and less formal compared to adult-care providers and this can sometimes make the transition difficult, she explained.

Type-1 diabetes, formerly known as juvenile diabetes, occurs when the pancreas makes little or no insulin; the disease typically emerges in childhood or adolescence. Type-2 diabetes, the more common form of the illness, is associated with aging and overweight and occurs when the body becomes less responsive to insulin.

Young people with type-1 diabetes must also take full responsibility for managing their diabetes, Robinson said, which includes injecting insulin multiple times a day, monitoring their glucose and paying close attention to diet and physical activity.

This can be overwhelming, especially when their previous caregivers were providing significant support during childhood and adolescence.

To assess the mental health toll of these burdens, the researchers used Quebec registries to identify people born between April 1982 and December 1998 without any mental illness diagnosed before age 15. The final analysis included 3,544 adolescents diagnosed with diabetes between ages 1 and 15, and nearly 1.4 million young people without diabetes.

The study team followed the youths from age 15 to 25 and found that in addition to increased risks for a mood disorder diagnosis or a suicide attempt, youth with diabetes were almost twice as likely to visit a psychiatrist, compared to peers without diabetes.

With diabetes, young people also had a 29% higher risk of being diagnosed with any psychiatric disorder. However, there were no differences between the groups in schizophrenia diagnoses.

Even without a diagnosis of diabetes, there is a lot of anxiety and depression nowadays in the adolescent population, said Dr. Anastassios G. Pittas, co-director of the Diabetes and Lipid Center, at Tufts Medical Center in Boston.

To be diagnosed, on top of that, with a chronic, incurable medical condition that affects essentially every minute of ones life has a huge impact, Pittas, who was not involved in the current study, told Reuters Health in a phone interview.

However, depending on the age of the child, a major medical diagnosis need not always have a negative impact, he added.

For Pittas, one major limitation of the study was the large range in ages at which diabetes was diagnosed, and he would have liked to see if there were differences in mental health risk on that basis.

Children diagnosed with diabetes at age 1 or 2 do not know life without diabetes, said Pittas, adding that kids diagnosed before ages 7 or 8 tend to do better than those diagnosed in the middle of adolescence.

Even so, the study authors note in their report, endocrinologists who treat young adults rarely receive a patients psychosocial summary as part of their referral documents from their pediatric colleagues.

As children with diabetes will inevitably transfer to adult care, pediatric and adult healthcare providers should be aware of the increased risk of developing mental health problems, Robinson said.

SOURCE: bit.ly/2uvRfH0 Diabetes Care, online December 16, 2019.

Originally posted here:
Suicide rates sharply higher than average in teens, young adults with diabetes - Reuters

Read More...

Tulsa diabetes advocate: ‘People are dying because they can’t afford their insulin.’ – kjrh.com

January 15th, 2020 1:41 am

TULSA, Okla. A medication keeping people alive costs too much to do just that.

The price for insulin is skyrocketing, which forces some diabetics to choose between their health or paying other bills.

One woman is working to change that. Megan Quickle is a diabetes advocate and lives with type 1 diabetes.

"People are dying because they can't afford their insulin. People are rationing their insulin, they're using less than they should be and it's taking a tremendous toll on their diabetes. This is not ok."

No one seems to know why insulin is so expensive, but the American Diabetes Association blames the complicated supply chain.

A lot of hands are involved, and many factors impact how much patients pay, including the amount and type of insulin, the delivery system used, and whether insurance is involved.

It's kind of a circle, loop that people are just pointing the finger at different people."

The A.D.A. calculates, more than 30 million Americans live with diabetes.

Quickle says lawmakers are working on a bill, but that it will only help a few dealing with this disease. She hopes state lawmakers will draft and pass an insulin affordability bill for all soon.

"If we are all using our same voice and advocating our government, saying, 'This is unacceptable,' maybe they'll listen to us."

There are ways to get cheaper insulin through different company programs like the Lily Diabetes Solution Center or Novo Nordisk . Patients are also encouraged to ask their pharmacies of any a rebate program.

Stay in touch with us anytime, anywhere.

Download our free app for Apple and Android and Kindle devices.

Sign up for newsletters emailed to your inbox. Select from these options: Breaking News, Severe Weather, School Closings, Daily Headlines and Daily Forecasts.

Follow us on Twitter

Like us on Facebook

Link:
Tulsa diabetes advocate: 'People are dying because they can't afford their insulin.' - kjrh.com

Read More...

Is It Safe to Eat Mango If You Have Diabetes? – Healthline

January 15th, 2020 1:41 am

Often referred to as the king of fruits, mango (Mangifera indica) is one of the most beloved tropical fruits in the world. Its prized for its bright yellow flesh and unique, sweet flavor (1).

This stone fruit, or drupe, has been primarily cultivated in tropical regions of Asia, Africa, and Central America, but its now grown across the globe (1, 2).

Given that mangoes contain natural sugar, many people wonder whether theyre appropriate for people with diabetes.

This article explains whether people with diabetes can safely include mango in their diets.

Mangoes are loaded with a variety of essential vitamins and minerals, making them a nutritious addition to almost any diet including those focused on improving blood sugar control (3).

One cup (165 grams) of sliced mango offers the following nutrients (4):

This fruit also boasts small quantities of several other important minerals, including magnesium, calcium, phosphorus, iron, and zinc (4).

Mango is loaded with vitamins, minerals, and fiber key nutrients that can enhance the nutritional quality of almost any diet.

Over 90% of the calories in mango come from sugar, which is why it may contribute to increased blood sugar in people with diabetes.

Yet, this fruit also contains fiber and various antioxidants, both of which play a role in minimizing its overall blood sugar impact (2).

While the fiber slows the rate at which your body absorbs the sugar into your blood stream, its antioxidant content helps reduce any stress response associated with rising blood sugar levels (5, 6).

This makes it easier for your body to manage the influx of carbs and stabilize blood sugar levels.

The glycemic index (GI) is a tool used to rank foods according to their effects on blood sugar. On its 0100 scale, 0 represents no effect and 100 represents the anticipated impact of ingesting pure sugar (7).

Any food that ranks under 55 is considered low on this scale and may be a better choice for people with diabetes.

The GI of mango is 51, which technically classifies it as a low GI food (7).

Still, you should keep in mind that peoples physiological responses to food vary. Thus, while mango can certainly be considered a healthy carb choice, its important to evaluate how you respond to it personally to determine how much you should include in your diet (8, 9).

Mango contains natural sugar, which can contribute to increased blood sugar levels. However, its supply of fiber and antioxidants may help minimize its overall blood sugar impact.

If you have diabetes and want to include mango in your diet, you can use several strategies to reduce the likelihood that it will increase your blood sugar levels.

The best way to minimize this fruits blood sugar effects is to avoid eating too much at one time (10).

Carbs from any food, including mango, may increase your blood sugar levels but that doesnt mean that you should exclude it from your diet.

A single serving of carbs from any food is considered around 15 grams. As 1/2 cup (82.5 grams) of sliced mango provides about 12.5 grams of carbs, this portion is just under one serving of carbs (4, 10).

If you have diabetes, start with 1/2 cup (82.5 grams) to see how your blood sugar responds. From there, you can adjust your portion sizes and frequency until you find the amount that works best for you.

Much like fiber, protein can help minimize blood sugar spikes when eaten alongside high carb foods like mango (11).

Mango naturally contains fiber but isnt particularly high in protein.

Therefore, adding a protein source may result in a lower rise in blood sugar than if you were to eat the fruit by itself (11).

For a more balanced meal or snack, try pairing your mango with a boiled egg, piece of cheese, or handful of nuts.

You can minimize mangos impact on your blood sugar by moderating your intake and pairing this fruit with a source of protein.

Most of the calories in mango come from sugar, giving this fruit the potential to raise blood sugar levels a particular concern for people with diabetes.

That said, mango can still be a healthy food choice for people trying to improve blood sugar control.

Thats because it has a low GI and contains fiber and antioxidants that may help minimize blood sugar spikes.

Practicing moderation, monitoring portion sizes, and pairing this tropical fruit with protein-rich foods are simple techniques to improve your blood sugar response if you plan to include mango in your diet.

See more here:
Is It Safe to Eat Mango If You Have Diabetes? - Healthline

Read More...

First year of the Montreal Heart Institute’s Diabetes Prevention Clinic supported by Sun Life Financial – Yahoo Finance

January 15th, 2020 1:41 am

Patients on the road to recovery from type 2 diabetes

MONTREAL , Jan. 13, 2020 /CNW/ - What if you were told you could reverse the course of type 2 diabetes through exercise and a healthy diet? That was the challenge this past year for patients at the Montreal Heart Institute's Diabetes Prevention Clinic supported by Sun Life Financial. The health team is thrilled with the progress achieved by its 180 participants during the clinic's first year.

"These are impressive results after just one year!I congratulate the patients who undertook this challenge and I thank the clinic's health care professionals who've helped guide them on their road to recovery," said Jacques Goulet , President of Sun Life Canada. "With so many Canadians affected by diabetes, Sun Life is committed to fighting the disease and its potentially serious complications. This initiative aligns with our purpose, which is to help our Clients achieve lifetime financial security and live healthier lives. "

"Lifestyle is better than medication for treating diabetes, and doesn't involve the side effects frequently associated with medication. The clinic delivers the best tools to patients, so they can minimize complications related to their disease," said Dr. Martin Juneau , Director of Prevention at the Montreal Heart Institute and Diabetes Prevention Clinic supervisor.

A multidisciplinary team of health practitioners meets periodically with participants and gives them the tools they need to make healthy lifestyle changes and improve their health. This multidisciplinary program is offered at the Montreal Heart Institute's EPIC Center, thanks to a donation of $450,000 from Sun Life.

A tailored program to meet growing demandThe Diabetes Prevention Clinic's mission is to turn the tide on diabetes through early detection and healthy lifestyle strategies. This program meets a growing demand for preventive services for patients with diabetes and prediabetes, chronic conditions currently affecting 1 in 3 Canadians. Cardiovascular disease is the most common complication and leading cause of death in patients with type 2 diabetes1. Fortunately, many studies show that type 2 diabetics who make lifestyle changes, including a high-quality diet, regular moderate-to-vigorous physical activity, no tobacco use and moderate alcohol consumption, reduce their risk of premature death from cardiovascular disease.

Diabetes is the 5th-leading cause of premature death in the world. Hyperglycemia from the onset of diabetes has multiple adverse effects on cardiovascular risk factors, including atherosclerosis, hypertension and dyslipidemia. These issues, together with the damage hyperglycemia causes to small blood vessels, mean type 2 diabetes increases the incidence of coronary heart disease by 2 to 4 times2.

Sun Life in the community At Sun Life, we are committed to building sustainable, healthier communities for life and we're proud to hold the Caring Company designation from Imagine Canada. Community wellness is an important part of our sustainability commitment and we believe that by actively supporting the communities in which we live and work, we can help build a positive environment for our Clients, Employees, advisors and shareholders. Our philanthropic support focuses on two key areas: health, with an emphasis on diabetes awareness, prevention, care and research initiatives through our Team Up Against DiabetesTM platform; and arts and culture, through our award-winning Making the Arts More AccessibleTM program. Since 2012, Sun Life has committed $31 million globally to support diabetes awareness, prevention, care and research initiatives. In Quebec our sponsorship and donation initiatives also focus on home economics and financial education.

We also partner with sports properties in key markets to further our commitment to healthy and active living. Our Employees and advisors take great pride in volunteering over 29,000 hours each year and contribute to making life brighter for individuals and families across Canada .

About the Montreal Heart InstituteFounded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training and prevention. It houses the largest cardiovascular research center in Canada , the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in the country. The Institute is affiliated with the University of Montreal and has more than 2,000 employees, including 245 doctors and more than 85 researchers.

Story continues

About the Montreal Heart Institute FoundationFounded in 1977, the Montreal Heart Institute Foundation raises and administers funds to support the Institute's priority and innovative projects and fight cardiovascular diseases, the world's number one cause of mortality. Its philanthropic events and the contributions of its donors have enabled this leading cardiovascular health care organization to become the largest cardiac research centre in the country. Since its creation, the Foundation has raised more than $283 million in donations. Its 27,514 donors helped make important discoveries and support specialists, professionals and researchers of the Institute to provide care at the cutting edge of technology to tens of thousands of patients in Quebec .

About the EPIC CenterThe MHI's EPIC Center is the largest centre for cardiovascular disease prevention in Canada , with more than 5500 registered members. The Center has a bit more than 80 employees and is part of the Prevention Branch of the Montreal Heart Institute. The centre is for healthy people who wish to keep it that way (primary prevention) as well as for patients who had a cardiac accident (readaptation and secondary prevention). The staff includes physicians, cardiologists, internists, emergency physicians, a physiologist, visiting professors, nurses, nutritionists, kinesiologists and rescuers.

Montreal Heart Institute Foundation Isabelle Pelletier 514 238-4178Ipelletier.pr@gmail.com

Sun LifeMylne Blanger514-904-9739mylene.belanger@sunlife.com

One year after the opening of the Montreal Heart Institutes Diabetes Prevention Clinic supported by Sun Life Financial, the health team is thrilled with the progress achieved by its participants. (CNW Group/Sun Life Financial Inc.)

Sun Life Financial Inc. (CNW Group/Sun Life Financial Inc.)

Montreal Heart Institute Foundation (CNW Group/Sun Life Financial Inc.)

SOURCE Sun Life Financial Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/13/c1437.html

Here is the original post:
First year of the Montreal Heart Institute's Diabetes Prevention Clinic supported by Sun Life Financial - Yahoo Finance

Read More...

Differences in Diabetes Care With and Without Certification as a Medical Home – Annals of Family Medicine

January 15th, 2020 1:41 am

PURPOSE The purpose of this study was to assess whether primary care practices certified as medical homes differ in having the practice systems required for that designation and in attaining favorable outcomes for their patients with diabetes, and whether those systems are associated with better diabetes outcomes.

METHODS We undertook a cross-sectional observational study, Understanding Infrastructure Transformation Effects on Diabetes (UNITED), of 586 Minnesota adult primary care practices, comparing those that were certified vs uncertified as medical homes in 2017, with analyses supplemented by previously published studies of these practices. We collected survey information about the presence of medical home practice systems for diabetes care and obtained 6 standardized measures of diabetes care collected yearly from all Minnesota practices.

RESULTS Of 416 practices completing questionnaires (71% of all practices, 92% of participating practices), 394 had data on diabetes care measures. Uncertified practices (39%) were more likely than certified practices to be rural, but their patient populations were similar. Certified practices had more medical home practice systems (79.2% vs 74.9%, P =.01) and were more likely to meet a composite measure of optimal diabetes care (46.8% vs 43.2%, P <.001). A 1-SD increase in presence of practice systems was associated with a 1.4% higher probability of meeting that measure (P <.001).

CONCLUSIONS Practices certified as medical homes have more practice systems and higher performance on diabetes care than uncertified practices, but there is extensive overlap, and any differences may reflect self-selection for certification.

In the last 10 years, the concept of a medical home for patients, a patient-centered medical home (PCMH), has resurfaced from its origins in pediatrics in 1967.1,2 The idea has received enormous interest in the United States as a potential vehicle for transforming the quality, experience, and costs of medical care. It has even led to creation of a large collaborative, the Patient-Centered Primary Care Collaborative, having more than 1,000 participating organizations,3,4 to promote its spread. There have been many demonstration projects and studies, and there are a variety of national and state processes to recognize or certify practices as PCMHs; however, the definitions and criteria for what constitutes a PCMH vary widely, and most studies lack comparison groups and suffer from volunteer bias.5 There are thus still many unanswered questions, including the following6,7: how do practice systems and outcomes in a PCMH-recognized practice differ from those in others without that designation? Is there a continuum of characteristics and performance among practices that are or are not PCMH recognized, or is there a clear distinction between these groups? And are these practice systems associated with diabetes care quality and outcomes?

The most widely used recognition for what constitutes a PCMH is the process established by the National Committee for Quality Assurance (NCQA).811 Minnesota was one of the first states to implement its own voluntary certification process for primary care practices in 2010, based on demonstration that a practice met 5 standards (criteria) after thorough review12: (1) continuous access and communications with patients and family; (2) an electronically searchable registry to identify care gaps and manage services; (3) care coordination for patient- and family-centered care; (4) care plans that involve patients with chronic or complex conditions; and (5) continuous improvement in patient satisfaction, outcomes, and cost-effectiveness.

These standards must be thoroughly described in an application and demonstrated to be in routine use during required site visits, both initially and at the 3-year recertification point. They are very similar to features the Agency for Healthcare Research and Quality has identified as the key functional attributes of a PCMH: comprehensive care, patient-centered care, coordinated care, accessible services, and quality and safety.13 As an incentive to apply for certification, Minnesota also developed a supplemental payment to certified practices for their Medicaid patients that depended on the complexity of their medical conditions. By late 2017, 61% of the 586 primary care practices in the state and border communities had been certified as a health care home (HCH), Minnesotas term for the PCMH.

The certification standards above require practice processes and systems that can be measured and reviewed triennially. Because all practices in Minnesota are also required to submit standardized data for public reporting on a variety of quality, satisfaction, and cost measures, these data provided us with an opportunity to test whether those practices that were adopters of HCH certification differed in systems and outcomes from uncertified practices. By exploring the differences between these 2 cohorts for adults with diabetes, we hoped to obtain answers to the 3 questions above.

We undertook a cross-sectional observational study, Understanding Infrastructure Transformation Effects on Diabetes (UNITED), of 586 primary care practices, 95% of them contained within 101 medical groups of varying size and type, that participated in Minnesotas 2017 public reporting on quality of care for adult patients with diabetes. Of these, 355 (61%) were certified as HCHs as of July 2017. Practices that were part of multisite medical groups were recruited through their medical directors.

Recruitment involved first sending a letter by Federal Express, followed in 1 week by an e-mail to the medical leader describing the study and its requirements and benefits for them. Participation required identification of the leaders at each practice site and encouragement for their completion of a single questionnaire in 2017. The only benefits for participants were provision of comparative information about their care processes and our findings on successful strategies for improving performance measures. This e-mail was followed by a telephone call from 1 of 2 physician authors (L.I.S. or K.A.P.) who are widely known to the states physicians. Follow-up calls, e-mails, or both were used until leaders verbally consented or declined, or we concluded that we would not be able to obtain an answer.

A leader of each participating practice was asked to complete an 81-question questionnaire asking about the presence of various practice systems to support high-quality care for patients with chronic conditions. The questionnaire was first created and tested for reliability by the National Committee for Quality Assurance as a way of assessing the presence of various features of the Chronic Care Model.14 It has been widely used in research and has been demonstrated to be associated with quality of care for patients with diabetes or depression, and with health care use and costs for patients with diabetes.1517

To create summary measures of practice systems in place, each question was scored as 0 (no such system was present) or 1 (a system was present). We limited our analysis to the 32 questions addressing diabetes care in the 5 domains required for certification in Minnesota (Table 1). Both the overall score and scores for each domain were calculated as a percentage of the total possible score, with equal weight for each question.

Practice Systems Questions for HCH Certification That Address Diabetes Care, in 5 Domains

Diabetes performance measures for each practice were obtained from MN Community Measurement (MNCM), the regions nonprofit organization for collecting and publicly reporting standardized performance measures for medical care.18 For diabetes, these measures include the proportions of diabetic patients having hemoglobin A1c control, having blood pressure control, using statins, using prophylactic aspirin, and not smoking, as well as a composite all-or-none measure of the proportion of patients meeting all 5 measures, indicating optimal diabetes care. Practices use direct data submission procedures to provide these patient-level measures for their diabetic population to MNCM as a part of the Minnesota Department of Health Statewide Quality Reporting and Measurement System.

We first computed summary statistics describing the practices and their diabetic patient populations by certification status, as well as their mean prevalence of practice systems and diabetes care measures. To account for differences in patient and practice characteristics, we also conducted multivariate analyses predicting the presence of practice systems (by certification status with practice characteristics as controls) and predicting patterns in optimal diabetes care (by certification status with both practice and patient characteristics as controls). Practice controls included size of the clinics medical group (large hospital-affiliated organization, small/medium-sized organization, single site), whether the practice was a Federally Qualified Health Center (FQHC), and location of the practice (urban, large rural town, small rural town, isolated rural town). Location was defined by practice ZIP code mapped to Rural-Urban Commuting Area codes (http://depts.washington.edu/uwruca). Patient controls included patient age, sex, record of a diagnosis of ischemic vascular disease, record of diagnosed depression, presence of type 1 diabetes, and insurance type (commercial, Medicare, Medicaid, dual Medicare-Medicaid, self-pay/uninsured). In addition, we mapped patient ZIP code to the American Community Survey19 to pick up measures of the income and education, wealth, and racial composition within the patients neighborhood.

The prevalence of practice systems, in total and by domain, was modeled at the practice level using linear regression with practice control variables. The probability of meeting the overall optimal diabetes care measure, and the probability of meeting each of its 5 components individually, was modeled at the patient level using a logit regression with patient and practice control variables. The practice survey data were cross-sectional (from 2017 only). Practice certification status did not control for volunteer bias, so those practices that were already providing better diabetes care may have been more likely to pursue HCH certification. For this reason, we estimated patient- level optimal diabetes care regression values including practice-level random effects to capture unobserved characteristics of the practices.

Of the 586 primary care practices providing care for adults with diabetes in Minnesota we targeted, 451 (77%) agreed to participate in the study. With diligent follow-up, we obtained completed questionnaires from 416 of these practices, for a 92% completion rate among participating practices and a 71% completion rate among the original 586 practices targeted.

Comparison of practices responding to the survey with nonresponding practices demonstrated that the former were more likely to be in large vertically integrated systems (74% vs 63%, P <.001) and to be located in urban settings (66% vs 43%, P <.001). Responding practices were also more likely to be HCH certified (64% vs 53%, P <.001) and to have patients meeting the optimal diabetes care measure (46% vs 43%, P <.001). Our use of multivariate regression analyses, however, should have normalized our results for observable differences between respondents and nonrespondents.

Among the 394 practices with both practice system data and performance measures for diabetes care, 258 (66%) were certified as HCHs whereas 136 (34%) were still uncertified. Characteristics of these practices by certification status are shown in Table 2. Certified practices were much more likely to be located in urban areas, but were no more likely to be independent or Federally Qualified Health Centers. Patient populations differed slightly by practice certification status, with small differences being statistically significant because of the large sample sizes. Certified practices did, however, have a larger share of patients covered by Medicaid and a smaller share covered by Medicare.

Characteristics of Participating Practices and Their Diabetic Patients, by HCH Certification Status and Overall

Table 3 shows summary statistics describing average HCH practice systems scores and diabetes care measures by certification status. These unadjusted results indicate that the HCH-uncertified practices had fewer practice systems in place, at least for care coordination and care plan development. The standard deviations for the practice systems scores were much larger than any differences between groups, however, indicating extensive overlap between the certification groups. Uncertified practices also had lower a level of the composite measure of optimal diabetes care, as well as lower levels of statin use and nonsmoking status.

Comparison of HCH Practice Systems Scores and Diabetes Care Measures

Table 4 allows more specific comparisons of the above differences after adjusting for differences in practice characteristics (medical group size, location, and Federally Qualified Health Center status) and, for care measures, differences in patient characteristics, in a multivariate analysis. This analysis confirmed the differences in overall practice systems, care coordination, and care plans, but access also now differed significantly by certification status; scores were a significant 4.5% to 9.5% higher for certified practices vs uncertified practices. Adjusted differences in care measures now were significantly higher for the certified group for all measures except for hypertension control, although the absolute differences were smaller (an absolute 0.1% to 5.1%) than those for systems scores.

Adjusted Differences in Practice System Scores and Diabetes Care Measures

Finally, we estimated the impact of an increase in practice systems score on the composite diabetes outcome measure, using patient-level logit regression analysis controlling for patient and practice characteristics (available from the corresponding author). As shown in Table 5, a 1-SD increase was significantly (P <.001) associated with a 1.4% increase in the probability of meeting the composite measure of optimal diabetes care, driven primarily by increases in the hypertension control and hemoglobin A1c control components of that composite.

Adjusted Association of a 1-SD Increase in Overall Practice Systems Score With Diabetes Care Measures

Our findings document that in a state with rigorous PCMH/HCH certification requirements passed by a majority of primary care practices, there were some differences between those that have been certified and those that have not 7 years after certification began. HCH-certified practices were much more likely to be in metropolitan areas and to have a higher proportion of patients covered by Medicaid, but a lower proportion covered by Medicare. Other differences in practice patient characteristics by age, sex, and prevalence of ischemic vascular disease or depression are small.

More importantly, when controlling for these differences, certified practices tended to have both more HCH-related practice systems and higher performance on some measures of the quality of diabetes care. The differences between group averages were not large, however, and there was considerable overlap between certified and uncertified practices with no clear boundary distinction between them as groups. Nevertheless, our finding that a higher practice systems score is associated with better diabetes performance measures suggests that practices wishing to improve their care and outcomes for patients with diabetes should consider how to best improve their practice systems, regardless of whether they are certified as medical homes. In another article, we describe additional analyses that identify those specific practice systems significantly associated with better results, both for all practices and for practice subtypes.20

Wiley et al21 have been studying the presence of what they call care management processes (similar to what we are calling practice systems) for chronic ill ness care in practices nationally and have reported that between 2006 and 2013, there were relatively large increases over time in the overall use of these processes for all sizes of practices. Similarly, Taliani et al22 conducted a qualitative study of care management in 25 practices with PCMH recognition. Interviews with personnel in the practices having the greatest improvement in diabetes performance measures found that they described more patient-centered care manager duties, better use of the electronic medical record for messaging and patient tracking, and stronger integration of the care manager into the care team, all systems that we measured in this study.

Although our study and the literature suggest that practice systems are associated with better performance, a key question is whether differences between certified and uncertified practices in these attributes are due to the certification process or whether they reflect self-selection as practices with more systems and better outcomes choose to become certified. Our cross-sectional study conducted at a point 7 years after certification began cannot answer that question, but other clues may help.

First, in a study of Minnesota HCH practices in 2010, we compared similar diabetes performance measures for the first 120 adult practices to be certified with the much larger sample of 518 practices that were uncertified then.12 At that time, the difference in optimal diabetes care composite scores between certified and uncertified practices was 8.0% vs the 3.5% difference in 2017. More importantly, the difference in these scores 2 years before certification was even larger for those that would become certified than for those that would not, so improvement over the period of attaining certification was actually greater for practices not working on certification.

Second, Shippee et al23 compared patient-level measures of optimal diabetes care for patients served by Minnesota HCH-certified practices with those served by uncertified practices in 2013. At that time, when there was a more equal split between certified and uncertified practices, the difference was 4.0%, similar to the 3.5% we found in 2017,12 suggesting that after certification, further improvement in diabetes scores is not greater for those that have achieved certification. This finding is also consistent with some additional testing using our data set (available from the corresponding author) showing little difference in performance between clinics achieving certification in the first year it was available (July 2010-June 2011) and clinics achieving certification more recently, indicating continued improvement is minimal once certification is achieved.

Third, as PCMH transformation was first gathering steam, the National Demonstration Project conducted a randomized trial among 36 clinics nationally that were highly interested in transformation. Results indicated that outcome measures were no better among clinics receiving extensive external help with that transformation than among those left to work on it on their own.24

Finally, Wang et al25 studied 150 small independent practices, comparing performance on 7 clinical quality measures in 2009 and 2011 between practices that had achieved PCMH recognition from NCQA and those that had not. They found significantly higher performance for PCMH practices at both time points, but the groups had improved at the same rate.

Taken together, these data suggest that practices that chose to be certified may have done so in part because they already had more systems and were performing better on outcome measures. If so, it would help to explain some of the confusing literature on whether medical home clinics provide better care. Instead, at least early adopters of innovations such as the medical home were already better. It also suggests that practices might be better off focusing limited resources on changes they believe will improve care and efficiency rather than on the work required for that designation. Once we have completed a second survey of our study practices and can measure changes over time, we may be able to address that hypothesis more directly.

Despite the unusually large sample of primary care practices in this study and the standardized measures of systems and outcomes, our analysis is limited by the cross-sectional nature of our data as well as the focus on a single state and a single chronic disease (diabetes). The practice systems survey is also limited by reliance on completion by a single participant with no objective verification of the presence of the systems being reported. In early tests of a very similar questionnaire, however, we demonstrated that such respondents did a good job of reporting, tending if anything to underreport practice systems more than overreport them.14

In conclusion, we have shown some differences in characteristics and practice systems, and in performance measures of diabetes care between practices that are certified as medical homes and those that are not. There also appears to be an association between systems and performance, so practices wanting to improve their care and performance measures should improve the number and function of practice systems, regardless of certification status. Most of the differences are small, however, so it is likely that none of these factors represent magic bullets that can be relied on to achieve large gains in performance over short periods of time. Organizational change is as slow as individual behavior change, but those interested in facilitating improvement need guidance on what changes will be most helpful, and that is the central goal of this ongoing project.

Conflicts of interest: authors report none.

To read or post commentaries in response to this article, see it online at http://www.AnnFamMed.org/content/18/1/66.

Funding support: Research reported in this publication was supported by the National Institute of Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health under Award Number R18DK110732.

Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Read more:
Differences in Diabetes Care With and Without Certification as a Medical Home - Annals of Family Medicine

Read More...

3 Top Diabetes Stocks to Watch in January – The Motley Fool

January 15th, 2020 1:41 am

Diabetes is a massive market in the healthcare sector. An estimated 415 million people have diabetes worldwide, and those numbers are growing. It's also an on-going healthcare issue, one that patients have to manage, often for the rest of their lives. As such, there is a lot of recurring revenue. It's not a bad idea to find a strong company focused on this vertical to add to your portfolio.

Over the last decade, one of the biggest stocks in healthcare has been diabetes specialistDexCom (NASDAQ:DXCM), a wireless health company that allows patients and doctors to track glucose levels in real-time. Another potential winner in this space isLivongo Health(NASDAQ:LVGO), an up-and-coming small-cap that sends updates, reminders, and coaching tips to all its clients with diabetes (and other health issues). And biotech companyProvention Bio(NASDAQ:PRVB)is hoping to get approval from the Food and Drug Administration (FDA) for a drug that delays the onset of type 1 diabetes. Read more to see if any of these stocks are buys right now.

Image source: Getty Images

DexCom, a $21 billion large-cap stock, has been dominant in healthcare for a long time. Over the last 10 years, shareholders have been rewarded with a 2,563% return. DexCom achieved that impressive return with a singular focus on diabetes. Traditionally, people with diabetes had to prick their finger to check their blood in order to monitor their insulin level. DexCom introduced a wireless device inserted under their skin. This sensor, called a continuous glucose monitor (CGM), is appreciated by patients because of its ease of use and valued by doctors because of its superior data and better health outcomes.

DexCom recently signed a distribution deal withWalgreens Boots Allianceto sell the CGM device. Patients insert a tiny sensor under the skin using an automatic applicator.DexCom's sensor starts automatically and continuously taking glucose readings in the patient's interstitial fluid. A micro-transmitter sends the data wirelessly to a receiver. Patients can read their own data in any connected smart device. The CGM can also be set to alert the patient if certain glucose levels are reached.

In its most recent quarter, DexCom reported $396 million in revenue for the quarter, 49% higher than the previous year. Net income was $60 million for the quarter. DexCom's main competition in this space is withAbbott Laboratories(NYSE:ABT)that sells a popular CGM device calledFreestyle Libre. Abbott's CEO Miles White predicted in a conference call last year that his company's device would achieve sales of $5 billion a year (which would dwarf DexCom's $1.35 billion). So far, DexCom's fantastic numbers suggest DexCom is still winning in the diabetes space. Even with competition, clearly the market opportunity is vast.

Livongo Health is a fascinating company and a rising star in personalized medicine. While unprofitable, the company has phenomenal revenue growth. It brought in $46 million in sales in its most recent quarter,up 148% year over year. Over 200,000 diabetes patients are on Livongo's messaging platform, up 118% year over year, and the company has 771 enterprise clients.The company is creating additional verticals in prediabetes, hypertension, weight management, and behavioral health. Livongo specializes in helping all patients with chronic conditions, giving them advice, coaching tips, and interpretations of data readouts.

The company has conducted 48 studies measuring return on investment (ROI) and found that 90% of its clients had positive ROI in the first year. Indeed, some corporate clients are so happy with Livongo's offering, the clients are offering to reduce or eliminate the co-pay for hypertension or diabetes drugs for their employees, as long as the employees subscribe to Livongo.

So far, Livongo's stock has been a disappointment, down 30% from the company's initial public offering in July 2019.The company has a $2.5 billion market cap, $400 million in cash, and no debt. Its price-to-sales ratio is 17, about the same as DexCom, while Livongo is growing revenues three times as fast.Gross margins are 74%, suggesting the company can become profitable at any time. Right now though, the company is focused on escalating its top-line growth.Livongo has formed partnerships with MDLIVE and Doctor on Demand to enable virtual access to doctors for all its clients, which will roll out in 2020.The future looks bright for Livongo Health.

Provention Bio is an interesting biotech focused on preventing diseases before they become acute. It's a tiny company right now, with a market cap of $658 million.But the stock has been running wild, up 741% last year. What caused the stock to take off? The company reported amazing results in its phase 2 study for Teplizumab, a drug designed to delay the onset of diabetes in at-risk patients.

In this long-term study, the median patients on placebo developed diabetes in two years. That's in sharp contrast to the group on Provention's drug. Those median patients developed diabetes in four years. In fact, 73% of the people on placebo developed diabetes, compared to 43% of those on Teplizumab. Thus the drug not only delayed the onset of diabetes, on average, but many patients avoided diabetes altogether. The numbers were so good, the FDA decided the company can file its new drug application on the basis of its phase 2 study.

Provention has no profits and no revenues, so like many biotech stocks, it has to be considered speculative. On the other hand, the risk/reward ratio is very intriguing, since the diabetes market is so large.

After all, diabetes is a $45 billion market in the U.S. alone.Worldwide, the diabetes market will surpass $85 billion by 2022. It's a huge market opportunity for all three of these companies. Of the three stocks, DexCom has the largest upside. The stock has quadrupled over the last two years, so patient investors might wait for a better price.

Read more:
3 Top Diabetes Stocks to Watch in January - The Motley Fool

Read More...

Finally, a pill that could fix the root cause of diabetes – ISRAEL21c

January 15th, 2020 1:41 am

Of the 463 million people in the world with diabetes, up to 95 percent have type 2 (T2D). In T2D, peripheral tissues mostly muscles are resistant to insulin, a hormone made by the pancreas to stabilize blood-sugar levels and enable the body to use and store sugar.

Medications available today treat the symptoms and complications of T2D but do not solve the core problem of insulin resistance.

Zygosid-50, a drug under development in Israel, could be the first to restore near-normal cellular sensitivity to insulin, without side effects.

Concenter BioPharma in Jerusalem is raising funds for clinical trials approved by the FDA based on evidence from earlier testing in animal models for T2D.

In December, Concenter Biopharma cofounder and CSO Prof. Mottie (Mordechai) Chevion won first place at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases.

The World Congress attracts the top researchers and clinicians, who understand the problem and the limited solutions available which arent really solutions at all, says Concenter Biopharma cofounder and CEO Dror Chevion, Motties son.

To receive the award out of 80 submitted abstracts and six chosen for presentation is a real vote of confidence in our science and our achievements, Dror Chevion tells ISRAEL21c. The people sitting in that conference will be the ones prescribing our drug to patients.

Concenter BioPharma cofounder and CSO Prof. Mottie Chevion, left, receiving his award from Dr. Zachary Bloomgarden at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases in Los Angeles, December 2019. Photo: courtesy

Mottie Chevion developed the nonsteroidal, anti-inflammatory Zygosid family of drugs in his lab at Hebrew University-Hadassah Medical Center in Jerusalem.

Zygosids work by robustly reducing insulin resistance and normalizing all diabetes-associated parameters to the normal range, says the professor. On the molecular level, Zygosid-50 is a potent anti-inflammatory drug that forces an intra-cellular exchange removal of bad free iron with zinc, depositing the zinc ion within the cells.

In 2015, some of the lab staff and their families successfully tried using Zygosid molecules topically for skin conditions including diabetic foot ulcers and psoriasis. They experienced no negative side effects.

My father felt it was inhumane not to try to bring these drugs from the lab to patients. He asked me to join him and take this initiative forward, says Dror Chevion.

The intellectual property was licensed to the inventors through the university and hospital tech-transfer companies. Silkim Pharma was set up as a holding company for the IP. Concenter Biopharma was founded as a subsidiary in 2019 to further develop and commercialize Zygosid-50 for treating and preventing T2D.

1 in 3 people has diabetes or prediabetes

Concenters US regulatory consultant, Dr. Susan Alpert, arranged meetings with the FDA in 2017 and 2018 to help determine which indication to focus on. The conclusion was to start with T2D and conduct clinical phase 1 and phase 2a trials in Israel while finalizing a pill formulation and completing preclinical toxicity studies.

One in three people in the world is diabetic or prediabetic, says Dror Chevion. The number is expected to reach 700 million by 2045. In the United States, 31 million people suffer from diabetes and 90 million are prediabetic. And the age of people contracting type 2 diabetes is getting younger and younger.

In animal trials, Zygosid-50 restored insulin sensitivity by better than 90%, bringing blood sugar into balance and lowering chronic and systemic inflammation levels. The drug also replenished zinc deficiency.

The FDA responded to Concenters investigational new drug (IND) application with a request for additional preclinical toxicity studies and more information on the drugs manufacturing process.

This is a great achievement for a small company, notes Dror Chevion.

We are working on accommodating those requests and making the final formulation of the drug as a pill. We plan to perform clinical studies here in Israel. Then we will submit another IND application to go to phase 2b, by the end of 2020. We are currently raising funds to do all of that.

Concenter was self-funded until six months ago. The company will launch a $5 million round for its T2D activities during 2020.

Concenter BioPharmas scientific advisory board includes three globally recognized diabetes experts: Dr. Peter Nawroth of Germany, Dr. Ralph DeFronzo from the United States, and Dr. Itamar Raz, chairman of the Israeli Council on Diabetes and the National Diabetes Prevention and Care Plan.

Diabetes is a global epidemic and is expected to grow, says Dror Chevion. The estimated cost of treating diabetes per year is over $850 billion. More than 150 companies are developing diagnostics or applications for diabetes, but there are no drugs to treat the actual problem of insulin resistance without side effects. This is what we are doing.

For more information, click here

More:
Finally, a pill that could fix the root cause of diabetes - ISRAEL21c

Read More...

A Type 2 diabetes diagnosis can overwhelm you. But with the right information, you can go on. – NBC News

January 15th, 2020 1:41 am

My mother had Type 2 diabetes. While she was living with and going through that, I didn't know about the strong connection between Type 2 diabetes and heart disease; I just worked to try to make her comfortable and manage the day to day. Perhaps if I had known that people living with diabetes are twice as likely to develop and die from cardiovascular disease, we could have asked her doctor different questions and been more diligent in helping her manage the risk to the complication that would eventually claim her life.

My mother made her transitionbecause of heart failure resulting from her Type 2 diabetes.

She was a woman who truly cared about people in her community. When I wasn't around, my mother spent time with all kinds of folks she had met especially young people she adored. When she passed, so many individuals she had met wrote me cards. I had no idea that she really spoke to them and brought so much into their lives. She was a simple and hard-working woman. She never made a lot of money, but she had an impact on the lives of those she met.

Get the think newsletter.

I decided that trying to help my mother continue making an impact on people's lives was a way I could honor her. That was why I teamed up with the American Diabetes Association and the American Heart Association to get the message out about the connection between Type 2 diabetes, heart disease and stroke. We are trying to help people like my mother.

For many people, when you hear news that's overwhelming like a diagnosis of diabetes you have one of two reactions: You either feel like your feet are being held to the fire and decide, Let's get moving, let's do something about this; or it's like, Oh my God, it's just all too much for me. The collaboration between the American Heart Association and the American Diabetes Association, called Know Diabetes by Heart, helps those people who are newly diagnosed with Type 2 diabetes (and their loved ones and family members) break down what to do next into bite-size portions, to get a handle on what it all means, so they can manage it and stay in the know.

One important thing we are trying to do is help people have conversations with their doctors about managing their cardiovascular health. I know from experience that it's even hard to know the right questions to begin those conversations. You can start by asking: What changes can I make today? What can I do before my next appointment? What changes can I make to take care of my heart in the long term? How will I know if those changes are having an effect?

Everyone is different so its important to always work closely with your doctor on the treatment thats right for you. Go to KnowDiabetesbyHeart.org for a discussion guide you can print out and take with you, or bring it up on your phone at your appointment.

The site also has stories from people who are dealing with this issue. They are sharing their personal stories to encourage you, and to remind you, that you are not alone. There are even good recipes on the site to help with the dietary changes. Like many people, nutrition was particularly difficult for my mother when dealing with her diabetes. You eat what you like for so many years 65 years, for her and then you get this diagnosis and you think: Now I'm supposed to change. How? Where do I start? This is one way.

The other part of this is that non-Hispanic blacks, Hispanic Americans and Native Americans are at a significantly higher risk to develop Type 2 diabetes, which researchers think is a result of a combination of factors, including genetics, lifestyle factors, environmental factors and socioeconomic conditions.

Beyond that, we all know that, in this country, there is a great disparity in access to and quality of health care, which also plays out when it comes to Type 2 diabetes and its complications.

For instance, a 2017 study by the Centers for Disease Control and Prevention showed that, though the risk of eye disease among Type 2 diabetes patients is well known, African American and Latino Medicaid patients with Type 2 diabetes were significantly less likely to be offered eye exams than white patients. A 2007 study in Family Medicine showed that even if you control for access to health care and socioeconomic status, Latino patients with Type 2 diabetes were less likely than white patients to have foot exams from their doctors, even though the risk of damage to patients' extremities is well known.

That is why it is so important that everyone has access to information, resources and support, and that they know what questions to ask their doctors and how to follow up. Through Know Diabetes by Heart we want to show people living with Type 2 diabetes that theyve been diagnosed with a new purpose. Yes, you have Type 2 diabetes and, yes, you can manage it and live your amazing life.

As told to THINK editor Megan Carpentier, condensed and edited for clarity.

Angela Bassett is an Academy-award nominated actor, a director and an activist. She is currently serving as an ambassador for Know Diabetes by Heart, a joint initiative of the American Heart Association and the American Diabetes Association.

Read the original:
A Type 2 diabetes diagnosis can overwhelm you. But with the right information, you can go on. - NBC News

Read More...

Page 749«..1020..748749750751..760770..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick